Terms: = Prostate cancer AND TG, Thyroglobulin AND Treatment
120 results:
1. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C; Manfredi M; Barboro P; Ghirimoldi M; Mennitto A; Martini V; Battioni A; Le Van M; Gobbato S; Branni C; Ayed RB; Pinato DJ; Catalano F; Zanardi E; Boccardo F; Gennari A
Sci Rep; 2023 Oct; 13(1):17791. PubMed ID: 37853018
[TBL] [Abstract] [Full Text] [Related]
2. Analytical HDR prostate brachytherapy planning with automatic catheter and isotope selection.
Frank CH; Ramesh P; Lyu Q; Ruan D; Park SJ; Chang AJ; Venkat PS; Kishan AU; Sheng K
Med Phys; 2023 Oct; 50(10):6525-6534. PubMed ID: 37650773
[TBL] [Abstract] [Full Text] [Related]
3. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines.
Atobatele AG; Tonoli E; Vadakekolathu J; Savoca MP; Barr M; Kataria Y; Rossanese M; Burhan I; McArdle S; Caccamo D; Verderio EAM
Cell Death Dis; 2023 May; 14(5):317. PubMed ID: 37160910
[TBL] [Abstract] [Full Text] [Related]
4. Hsa_circ_0063329 inhibits prostate cancer growth and metastasis by modulating the miR-605-5p/tgif2 axis.
Lv D; Cen S; Yang S; Zou Z; Zhong J; Pan Z; Deng N; Li Y; Wu K; Wang J; Liu P
Cell Cycle; 2023 May; 22(9):1101-1115. PubMed ID: 36740902
[TBL] [Abstract] [Full Text] [Related]
5. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
Karkeet RM; Zekri AN; Sayed-Ahmed MM; Sherif GM; Salem SE; Abdelbary A; Fouad MA; Saad SY
PLoS One; 2022; 17(12):e0278282. PubMed ID: 36480560
[TBL] [Abstract] [Full Text] [Related]
6. AAPM task group report 303 endorsed by the ABS: MRI implementation in HDR brachytherapy-Considerations from simulation to treatment.
Prisciandaro J; Zoberi JE; Cohen G; Kim Y; Johnson P; Paulson E; Song W; Hwang KP; Erickson B; Beriwal S; Kirisits C; Mourtada F
Med Phys; 2022 Aug; 49(8):e983-e1023. PubMed ID: 35662032
[TBL] [Abstract] [Full Text] [Related]
7. Implementation of TG-218 for patient-specific quality assurance tolerance and action limits determination: Gamma passing rate evaluation using 3DVH software.
Stasinou D; Patatoukas G; Kollaros N; Diamantopoulos S; Kypraiou E; Kougioumtzopoulou A; Kouloulias V; Efstathopoulos E; Platoni K
Med Phys; 2022 Jul; 49(7):4322-4334. PubMed ID: 35560362
[TBL] [Abstract] [Full Text] [Related]
8. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract] [Full Text] [Related]
9. Head-to-Head Comparison of
Pitalua-Cortes Q; García-Perez FO; Vargas-Ahumada J; Gonzalez-Rueda S; Gomez-Argumosa E; Ignacio-Alvarez E; Soldevilla-Gallardo I; Torres-Agredo L
Front Endocrinol (Lausanne); 2021; 12():794759. PubMed ID: 35002972
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Application of Confidence Interval for Monitoring Changes in Tumor Markers to Determine the Responsiveness to cancer treatment.
Cho J; Seo DM; Uh Y
Ann Clin Lab Sci; 2021 May; 51(3):321-328. PubMed ID: 34162561
[TBL] [Abstract] [Full Text] [Related]
11. A review of dosimetric impact of implementation of model-based dose calculation algorithms (MBDCAs) for HDR brachytherapy.
Yousif YAM; Osman AFI; Halato MA
Phys Eng Sci Med; 2021 Sep; 44(3):871-886. PubMed ID: 34142317
[TBL] [Abstract] [Full Text] [Related]
12. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract] [Full Text] [Related]
13. Based on biomedical index data: Risk prediction model for prostate cancer.
Guo H; Jia X; Liu H
Medicine (Baltimore); 2021 Apr; 100(17):e25602. PubMed ID: 33907111
[TBL] [Abstract] [Full Text] [Related]
14. Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles.
Tegally H; Kensler KH; Mungloo-Dilmohamud Z; Ghoorah AW; Rebbeck TR; Baichoo S
PLoS One; 2020; 15(11):e0242780. PubMed ID: 33232371
[TBL] [Abstract] [Full Text] [Related]
15. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract] [Full Text] [Related]
16. A Machine Learning method for relabeling arbitrary DICOM structure sets to TG-263 defined labels.
Sleeman Iv WC; Nalluri J; Syed K; Ghosh P; Krawczyk B; Hagan M; Palta J; Kapoor R
J Biomed Inform; 2020 Sep; 109():103527. PubMed ID: 32777484
[TBL] [Abstract] [Full Text] [Related]
17. New core configuration for the fabrication of
Daruich de Souza C; Alberto Zeituni C; Feher A; Augusto Moura J; Luiz da Costa O; Angelocci LV; Rostelato MECM
Appl Radiat Isot; 2020 Nov; 165():109307. PubMed ID: 32738753
[TBL] [Abstract] [Full Text] [Related]
18. Castration aggravates insulin resistance, reduces immune function and improves quality of life of prostate cancer patients.
Ma Z; Jiang M; Chen J; Shen G; Zhou Y; Li G
J BUON; 2020; 25(2):1148-1154. PubMed ID: 32521919
[TBL] [Abstract] [Full Text] [Related]
19. Early 3-month treatment with comprehensive physical therapy program restores continence in urinary incontinence patients after radical prostatectomy: A randomized controlled trial.
Soto González M; Da Cuña Carrera I; Gutiérrez Nieto M; López García S; Ojea Calvo A; Lantarón Caeiro EM
Neurourol Urodyn; 2020 Jun; 39(5):1529-1537. PubMed ID: 32442334
[TBL] [Abstract] [Full Text] [Related]
20. GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy.
Siebert FA; Kirisits C; Hellebust TP; Baltas D; Verhaegen F; Camps S; Pieters B; Kovács G; Thomadsen B
Radiother Oncol; 2020 Jul; 148():51-56. PubMed ID: 32335363
[TBL] [Abstract] [Full Text] [Related]
[Next]
